Clik here to view.
Merck’s Consumer Health Division Breaks $1bn Barrier Through Transition of...
Smart Multimedia Gallery Floratil and Neurobion; brands that have been incorporated into Merck Consumer Health (Photo: Business Wire) View and Share Photo Download Small DARMSTADT, Germany Merck’s...
View ArticleClik here to view.
22nd Century集团普通股获准在NYSE MKT上市
纽约州克拉伦斯 (美国商业资讯)–22nd Century Group, Inc. (OTCQB:XXII)今日宣布，公司普通股已获批在纽交所市场(NYSE MKT)上市。该公司普通股预计于2014年3月11日周二在纽交所市场开始交易，股票代码为公司目前的代码XXII。在纽交所市场上市之后，22nd Century集团将停止在场外柜台交易系统(OTCBB)和OTCQB交易。 22nd...
View ArticleClik here to view.
独立研究により、V.A.C. VeraFlo™ Therapyが従来のV.A.C.® Therapyより有効であることが判明
サンアントニオ （ビジネスワイヤ） — キネティック・コンセプツは本日、Plastic and Reconstructive Surgery誌に掲載された独立の後ろ向き研究で、陰圧創傷治療システムV.A.C.Ulta™を使用したV.A.C. VeraFlo™ Therapyによる補助療法が、従来のV.A.C.®...
View ArticleClik here to view.
独立研究显示：与传统V.A.C.®疗法相比，V.A.C. VeraFlo™ 疗法更为有益
圣安东尼奥哥 (美国商业资讯) –Kinetic Concepts 公司今天宣布，Plastic and Reconstructive Surgery（《整形与整复外科》杂志）上发表的一项独立回顾性研究表明：采用 V.A.C.Ulta™ 负压伤口疗法系统的V.A.C. VeraFlo™ 疗法辅助治疗的手术室（OR）就诊次数、至最终手术时间和留诊时间显著低于传统V.A.C.®疗法。*...
View ArticleClik here to view.
Clik here to view.
Clinical Network Services (CNS) Opens New UK Office and Expands Core Services
BRISBANE, Australia Clinical Network Services (CNS) an integrated product development company based in Australia and New Zealand providing broad services in the planning, implementation and delivery...
View ArticleClik here to view.
Fibrotech announces positive Phase Ia results for anti-fibrotic FT011
MELBOURNE, Australia Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead...
View ArticleClik here to view.
Mainstay Medical Begins Clinical Trial of ReActiv8® for People with Chronic...
Smart Multimedia Gallery Peter Crosby, CEO, Mainstay Medical (Photo: Business Wire) View and Share Photo Download Small DUBLIN Mainstay Medical today announced that it has secured approval from...
View ArticleClik here to view.
WuXi PharmaTech Purchases an Illumina HiSeq X Ten Sequencing System
SAN DIEGO & SHANGHAI Illumina, Inc. (NASDAQ:ILMN) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with...
View ArticleClik here to view.
Catalent Announces Agreement for One of the First Regenerative Therapies to...
SOMERSET, N.J. Catalent Pharma Solutions, the global leader in advanced delivery technologies and development solutions for drug, biologic and consumer health products, today announced an agreement...
View ArticleClik here to view.
Clik here to view.
ResearchDx, the Leading Contract Diagnostics Organization, Sponsors the Asia...
SINGAPORE ResearchDx, LLC of Irvine, California, USA today announced its sponsorship and attendance at the Asia BioPharm 2014 Convention in Singapore as part of its focus on the important Asian...
View ArticleClik here to view.
R-Tech Ueno: Announcement of Collaborative Research with Keio University for...
TOKYO R-Tech Ueno, Ltd. (JASDAQ:4573): We announce the launch of a collaborative research on graft-versus-host disease (GVHD) with Professor Kazuo Tsubota’s group, Department of Ophthalmology, Keio...
View ArticleClik here to view.
Almac Expands Asia Pacific Operations, Establishes Regional Operations Centre...
CRAIGAVON, Northern Ireland Almac today announced the expansion of its clinical services and technologies capabilities to include on-the-ground leadership as well as technical, project and...
View ArticleClik here to view.
22ndセンチェリー・グループ、子会社のグッドリッチ・タバコ・カンパニーが米国政府のたばこ製品製造許可を取得
米ニューヨーク州クラレンス （ビジネスワイヤ） — 22ndセンチェリー・グループ（OTCQB: XXII）は本日、完全所有子会社のグッドリッチ・タバコ・カンパニーが米国財務省酒類タバコ税貿易管理局からたばこ製品を製造する米国政府の許可（TTB許可）を得たと発表しました。...
View ArticleClik here to view.
Clinipace Worldwide Expands into Asia with Acquisition of Choice Pharma
MORRISVILLE, N.C. Clinipace Worldwide, a global digital contract research organization (dCRO), announced today the closing of its merger with Choice Pharma, a Pan-Asian contract research...
View ArticleClik here to view.
M&A Slowdown and Drop in FDA Approvals Stifles Growth of Medtech Sector in 2013
LONDON & BOSTON & TOKYO At the half-year mark, the medtech sector was on course for its worst year in a decade in terms of M&A activity, EP Vantage concluded last fall in its Half Year...
View ArticleClik here to view.
Record-Breaking Valuations and Surging Share Prices Drive Strong Pharma and...
LONDON & BOSTON & TOKYO The cautious optimism of 2012 turned into a fully fledged biotech boom in 2013, marked by surging company valuations in the U.S. and the opening of the IPO...
View ArticleClik here to view.
22nd Century Group子公司Goodrich Tobacco获得生产烟草产品的联邦许可
纽约州克拉伦斯 (美国商业资讯)–22nd Century Group, Inc. (OTCQB: XXII)今天宣布，全资子公司Goodrich Tobacco Company已获得美国财政部烟酒税收贸易局颁发的生产烟草产品的联邦许可（“TTB许可”）。 如此前公布，22nd Century Group签订了一份成员权益收购协议，收购北卡罗莱纳州有限责任公司NASCO Products,...
View ArticleClik here to view.
领先的合同诊断学组织赞助2014年亚洲生物制药大会
新加坡 (美国商业资讯)–总部位于加州Irvine的ResearchDx, LLC今天宣布，该公司将赞助并参加在新加坡召开的2014年亚洲生物制药大会，这是该公司专注于重要的亚洲生物制药和诊断学市场的一部分。 ResearchDx将出席于3月10-13日在新加坡召开的2014年亚洲生物制药大会。ResearchDx联合创始人兼负责人Philip...
View Article